XR Securities’s AstraZeneca AZN Stock Holding History

XR Securities’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,300	Closed	-$312K	–	421
2022 Q4	$312K	Buy	+2,300	New	+$288K	0.03%	360
2022 Q1	–	Sell	-6,550	Closed	-$24K	–	358
2021 Q4	$24K	Sell	6,550 -1,250	-16%	-$147K	﹤0.01%	360
2021 Q3	$53K	Sell	7,800 -1,800	-19%	-$210K	0.02%	277
2021 Q2	$143K	Sell	9,600 -14,800	-61%	-$1.62M	0.06%	223
2021 Q1	$40K	Buy	24,400 +6,600	+37%	+$663K	﹤0.01%	355
2020 Q4	$51K	Buy	17,800 +7,350	+70%	+$779K	﹤0.01%	296
2020 Q3	$31K	Buy	+10,450	New	+$1.16M	﹤0.01%	202
2020 Q1	–	Sell	-6,650	Closed	-$82K	–	209
2019 Q4	$82K	Buy	6,650 +1,200	+22%	+$113K	0.01%	153
2019 Q3	$40K	Sell	5,450 -4,050	-43%	-$351K	0.01%	168
2019 Q2	$52K	Sell	9,500 -1,400	-13%	-$110K	0.01%	180
2019 Q1	$60K	Buy	+10,900	New	+$859K	0.01%	195

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

XR Securities's AZN Position: Q1 2023 in Review

XR Securities sold out of AstraZeneca (AZN) in Q1 2023, closing a stake of 1,688 shares — an estimated $229K sold.

XR Securities first reported a position in AZN in Q1 2020 and held it in 9 quarters. The position peaked at $1.36M in Q4 2020. 1,056 funds tracked by Wall St. Rank hold AZN as of Q1 2023.

XR Securities reported no remaining AstraZeneca position as of Q1 2023 after selling out during the quarter.
XR Securities sold 1,688 AstraZeneca shares in Q1 2023, an estimated $229K.
XR Securities first reported a position in AstraZeneca in Q1 2020 and held it in 9 quarters.
XR Securities's AstraZeneca position peaked at $1.36M in Q4 2020.
1,056 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2023.

Based on XR Securities's 13F filing for Q1 2023, filed 2 May 2023.